BeOne Medicines director awarded 18,980 RSUs

Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares on a Form 4 filing. These shares underlie restricted share units granted at a price of $0.00 per share as a compensation award rather than a market purchase.

The restricted share units will become fully vested on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless accelerated under the company’s Independent Non-Executive Director Compensation Policy.

Insider Trade Summary

Grant/Award: 18,980 shares

Grant/Award 1 txn

Insider Mooney Elizabeth Fisher

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,980	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 18,980 shares (Direct)

Footnotes (1)

1. F1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Key Figures

RSU underlying shares: 18,980 shares Grant price: $0.00 per share Post-grant holdings: 18,980 shares

3 metrics

RSU underlying shares 18,980 shares Restricted share units granted to director Elizabeth Fisher Mooney

Grant price $0.00 per share Price per Ordinary Share for the RSU-related securities

Post-grant holdings 18,980 shares Total Ordinary Shares reported following the transaction

Key Terms

restricted share units, grant date, Independent Non-Executive Director Compensation Policy

3 terms

restricted share units financial

"Represents securities underlying restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

grant date financial

"shall become fully vested on the earlier to occur of the first anniversary of the grant date"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

Independent Non-Executive Director Compensation Policy financial

"triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BeOne Medicines (ONC) disclose for Elizabeth Fisher Mooney?

BeOne Medicines disclosed that director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares. These shares underlie restricted share units granted at a price of $0.00 per share as part of director compensation, not an open-market stock purchase.

How many BeOne Medicines (ONC) shares are tied to the new restricted share units?

The grant covers securities underlying 18,980 Ordinary Shares of BeOne Medicines. These are represented by restricted share units awarded to director Elizabeth Fisher Mooney, with the entire amount reported as directly owned following the transaction on the Form 4 filing.

When do Elizabeth Fisher Mooney’s BeOne Medicines (ONC) restricted share units vest?

The restricted share units vest fully on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. This schedule sets a clear time-based or meeting-based vesting trigger for the full 18,980 underlying Ordinary Shares.

What happens to the BeOne Medicines (ONC) restricted share units if the director leaves the board?

All vesting of the restricted share units ceases if the director resigns from the board or otherwise stops serving as a director. An exception applies if there is a triggering event of accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy.

Did BeOne Medicines (ONC) director Elizabeth Fisher Mooney buy or sell shares on the market?

The Form 4 reflects a grant or award acquisition of securities underlying 18,980 Ordinary Shares at a price of $0.00 per share. It does not report an open-market purchase or sale but rather a compensation-related award in the form of restricted share units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mooney Elizabeth Fisher

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		18,980	A	$0	18,980	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)